Hemophagocytic Lymphohistiocytosis is Associated with Deficiency and Closed Conformation of ADAMTS-13

Overview

Journal Res Pract Thromb Haemost

Publisher Elsevier

Date 2024 Feb 19

PMID 38371335

Authors

Amelie Launois

Sandrine Valade

Eric Mariotte

Lionel Galicier

Elie Azoulay

Elien Roose

Karen Vanhoorelbeke

Agnes Veyradier

Berangere S Joly

Affiliations

Soon will be listed here.

Abstract

Background: A disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13 (ADAMTS-13) is the specific von Willebrand factor-cleaving protease and circulates in a closed and latent conformation due to a spacer/CUB1 domain interaction. ADAMTS-13 is allosterically activated after binding of its substrate or antibodies, inducing an open conformation. Recently, we suggested a potential role of plasmin (fibrinolysin) in hemostasis disorders reported in most patients with hemophagocytic lymphohistiocytosis (HLH), a rare and life-threatening condition related to a severe systemic inflammatory state. Most patients with HLH had a partial ADAMTS-13 deficiency, and plasmin could induce a truncation of the C-terminal part of ADAMTS-13 and thus an open conformation.

Objectives: To understand the effect of plasmin on ADAMTS-13, our study aimed to investigate ADAMTS-13 conformation in patients with HLH.

Methods: Forty-five critically ill patients with HLH were prospectively enrolled between April 2015 and December 2018. ADAMTS-13 activity was measured by fluorescent resonance energy transfer-VWF73 assay, ADAMTS-13 antigen, and conformation with our homemade 3H9-enzyme-linked immunosorbent assay and 1C4-enzyme-linked immunosorbent assay.

Results: ADAMTS-13 activity ranged from <10 to 65 IU/dL, and 41 of the 45 patients had a quantitative deficiency in ADAMTS-13 (activity <50 IU/dL). Twenty patients had a severe ADAMTS-13 deficiency (activity <20 IU/dL). ADAMTS-13 conformation was folded in all patients under normal conditions. Surprisingly, the switch of ADAMTS-13 conformation expected with the monoclonal antibody 17G2 (anti-CUB1) was disturbed in 6 patients (activity <20 IU/dL).

Conclusion: Our study reported that ADAMTS-13 conformation is closed in HLH and provides an indirect proof that plasmin is not able to massively degrade ADAMTS-13. Further studies on glycosylation and citrullination profiles of ADAMTS-13 are needed to understand their role in HLH.

References

Clark C, Mebius M, de Maat S, Tielens A, de Groot P, Urbanus R . Truncation of ADAMTS13 by Plasmin Enhances Its Activity in Plasma. Thromb Haemost. 2018; 118(3):471-479. DOI: 10.1055/s-0038-1627460. View

Roose E, Schelpe A, Tellier E, Sinkovits G, Joly B, Dekimpe C . Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. Blood. 2020; 136(3):353-361. DOI: 10.1182/blood.2019004221. View

Zheng X, Chung D, Takayama T, Majerus E, Sadler J, Fujikawa K . Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001; 276(44):41059-63. DOI: 10.1074/jbc.C100515200. View

Tsai H, Lian E . Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998; 339(22):1585-94. PMC: 3159001. DOI: 10.1056/NEJM199811263392203. View

Gloude N, Dandoy C, Davies S, Myers K, Jordan M, Marsh R . Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy. J Clin Immunol. 2020; 40(5):699-707. PMC: 7245179. DOI: 10.1007/s10875-020-00789-4. View

Minoia F, Tibaldi J, Muratore V, Gallizzi R, Bracaglia C, Arduini A . Thrombotic Microangiopathy Associated with Macrophage Activation Syndrome: A Multinational Study of 23 Patients. J Pediatr. 2021; 235:196-202. DOI: 10.1016/j.jpeds.2021.04.004. View

Valade S, Joly B, Veyradier A, Fadlallah J, Zafrani L, Lemiale V . Coagulation disorders in patients with severe hemophagocytic lymphohistiocytosis. PLoS One. 2021; 16(8):e0251216. PMC: 8330932. DOI: 10.1371/journal.pone.0251216. View

Ercig B, Arfman T, Hrdinova J, Wichapong K, Reutelingsperger C, Vanhoorelbeke K . Conformational plasticity of ADAMTS13 in hemostasis and autoimmunity. J Biol Chem. 2021; 297(4):101132. PMC: 8449270. DOI: 10.1016/j.jbc.2021.101132. View

Peigne V, Azoulay E, Coquet I, Mariotte E, Darmon M, Legendre P . The prognostic value of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) deficiency in septic shock patients involves interleukin-6 and is not dependent on disseminated intravascular coagulation. Crit Care. 2013; 17(6):R273. PMC: 4056532. DOI: 10.1186/cc13115. View

10.

Mariotte E, Azoulay E, Galicier L, Rondeau E, Zouiti F, Boisseau P . Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol. 2016; 3(5):e237-45. DOI: 10.1016/S2352-3026(16)30018-7. View

11.

Joly B, Coppo P, Veyradier A . Thrombotic thrombocytopenic purpura. Blood. 2017; 129(21):2836-2846. DOI: 10.1182/blood-2016-10-709857. View

12.

Petri A, Kim H, Xu Y, de Groot R, Li C, Vandenbulcke A . Crystal structure and substrate-induced activation of ADAMTS13. Nat Commun. 2019; 10(1):3781. PMC: 6706451. DOI: 10.1038/s41467-019-11474-5. View

13.

Steffen C, Koch N, Eckardt K, Amann K, Seelow E, Schreiber A . Hemophagocytic lymphohistiocytosis and thrombotic microangiopathy after parvovirus B19 infection and renal transplantation: a case report. BMC Nephrol. 2021; 22(1):337. PMC: 8506469. DOI: 10.1186/s12882-021-02538-0. View

14.

Chang J . TTP-like syndrome: novel concept and molecular pathogenesis of endotheliopathy-associated vascular microthrombotic disease. Thromb J. 2018; 16:20. PMC: 6087012. DOI: 10.1186/s12959-018-0174-4. View

15.

Levi M, Scully M, Singer M . The role of ADAMTS-13 in the coagulopathy of sepsis. J Thromb Haemost. 2018; 16(4):646-651. DOI: 10.1111/jth.13953. View

16.

South K, Luken B, Crawley J, Phillips R, Thomas M, Collins R . Conformational activation of ADAMTS13. Proc Natl Acad Sci U S A. 2014; 111(52):18578-83. PMC: 4284544. DOI: 10.1073/pnas.1411979112. View

17.

Nowak A, OBrien H, Henne P, Doerr A, Vanhoorelbeke K, Laffan M . ADAMTS-13 glycans and conformation-dependent activity. J Thromb Haemost. 2017; 15(6):1155-1166. DOI: 10.1111/jth.13688. View

18.

Sorvillo N, Mizurini D, Coxon C, Martinod K, Tilvawala R, Cherpokova D . Plasma Peptidylarginine Deiminase IV Promotes VWF-Platelet String Formation and Accelerates Thrombosis After Vessel Injury. Circ Res. 2019; 125(5):507-519. PMC: 6697196. DOI: 10.1161/CIRCRESAHA.118.314571. View

19.

Muia J, Zhu J, Gupta G, Haberichter S, Friedman K, Feys H . Allosteric activation of ADAMTS13 by von Willebrand factor. Proc Natl Acad Sci U S A. 2014; 111(52):18584-9. PMC: 4284596. DOI: 10.1073/pnas.1413282112. View

20.

Henter J, Horne A, Arico M, Egeler R, Filipovich A, Imashuku S . HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2006; 48(2):124-31. DOI: 10.1002/pbc.21039. View